Who
Peter Wirth
Director
Company insider
Files Form 4 as: Director, Zai Lab; Director, Syros Pharmaceuticals; Director, Forma Therapeutics Holdings; Director, Synageva Biopharma; Exec VP,Legal & Corporate Dev., Genzyme.
In numbers
- Trades disclosed
- 85
- Buys
- 3
- Sells
- 5
- Bought
- $571K
- Sold
- $18.5M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 1 Dec 2005
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | —22,371 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | —22,371 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | —10,831 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | —21,253 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | Syros Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | Syros Pharmaceuticals | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 29 Jun 2023filed 30 Jun 2023 | ZLAB Zai LabBiotechnology | SEC FORM 4 Code A | $500K18,903 at $26.45 | filing |
| 1 Jun 2023filed 2 Jun 2023 | Syros Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | Syros Pharmaceuticals | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 8 Dec 2022filed 9 Dec 2022 | ZLAB Zai LabBiotechnology | SEC FORM 4 Sold | $136K3,852 at $35.37 | filing |
| 8 Dec 2022filed 9 Dec 2022 | ZLAB Zai LabBiotechnology | SEC FORM 4 Sold | $141K4,000 at $35.33 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —14,026 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —28,053 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —17,533 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —8,375 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —6,750 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdings | SEC FORM 4 Code U | —127,665 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdings | SEC FORM 4 Code U | —7,250 | filing |
| 16 Sep 2022filed 19 Sep 2022 | Syros Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 16 Sep 2022filed 19 Sep 2022 | Syros Pharmaceuticals | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.